# Immunoglobulin G1 Fc glycosylation as an early hallmark of severe **COVID-19**

Tamas Pongracz<sup>1,\*</sup>, Jan Nouta<sup>1</sup>, Wenjun Wang<sup>1</sup>, Krista. E. van Meijgaarden<sup>4</sup>, Federica Linty<sup>2,3</sup>, 1

Gestur Vidarsson<sup>2,3</sup>, Simone A. Joosten<sup>4</sup>, Tom H. M. Ottenhoff<sup>4</sup>, Cornelis H. Hokke<sup>5</sup>, Jutte J. C. 2

de Vries<sup>6</sup>, Sesmu M. Arbous<sup>7</sup>, Anna H. E. Roukens<sup>7</sup>, Manfred Wuhrer<sup>1</sup> in collaboration with 3

- 4 **BEAT-COVID<sup>#</sup>** and COVID-19<sup>&</sup> groups
- 5 <sup>1</sup>Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands
- 6 <sup>2</sup>Dept. of Experimental Immunohematology, Sanguin Research, Amsterdam, Netherlands
- 7 <sup>3</sup>Landsteiner Laboratory, Amsterdam University Medical Center, Amsterdam, Netherlands
- 8 <sup>4</sup>Dept. of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands
- 9 <sup>5</sup>Dept. of Parasitology, Leiden University Medical Center, Leiden, Netherlands
- 10 <sup>6</sup>Dept. of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands
- 11 <sup>7</sup>Dept. of Intensive Care, Leiden University Medical Center, Leiden, Netherlands
- **#BEAT-COVID group** (in alphabetical order, investigators): B. M. van den Berg<sup>2</sup>, S. Cannegieter<sup>3</sup>, 12
- 13
- 14
- C. M. Cobbaert<sup>4</sup>, A. van der Does<sup>5</sup>, J. J. M. van Dongen<sup>6</sup>, H. C. J. Eikenboom<sup>7</sup>, M. C. M. Feltkamp<sup>8</sup>, A. Geluk<sup>9</sup>, J. J. Goeman<sup>10</sup>, M. Giera<sup>11</sup>, T. Hankemeier<sup>12</sup>, M. H. M. Heemskerk<sup>13</sup>, P. S. Hiemstra<sup>5</sup>, J. J. Janse<sup>14</sup>, S. P. Jochems<sup>14</sup>, M. Kikkert<sup>8</sup>, L. Lamont<sup>12</sup>, J. Manniën<sup>10</sup>, M. R. del Prado<sup>1</sup>, N. Queralt 15
- Rosinach<sup>15</sup>, M. Roestenberg<sup>14</sup>, M. Roos<sup>15</sup>, H. H. Smits<sup>14</sup>, E. J. Snijder<sup>8</sup>, F. J. T. Staal<sup>6</sup>, L. A. Trouw<sup>6</sup>, R. Tsonaka<sup>10</sup>, A. Verhoeven<sup>11</sup>, L. G. Visser<sup>9</sup>, J. J. C. de Vries<sup>8</sup>, D. J. van Westerloo<sup>1</sup>, J. Wigbers<sup>1</sup>, H. 16
- 17
- J. van der Wijk<sup>10</sup>, R. C. van Wissen<sup>4</sup>, M. Yazdanbakhsh<sup>14</sup>, M. Zlei<sup>6</sup> 18
- <sup>1</sup>Dept. of Intensive Care, Leiden University Medical Center, Leiden, Netherlands 19
- 20 <sup>2</sup>Dept. of Internal Medicine, Nephrology, Leiden University Medical Center, Leiden, Netherlands
- 21 <sup>2</sup>Dept. of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
- 22 <sup>4</sup>Dept. of Clinical Chemistry, Leiden University Medical Center, Leiden, Netherlands
- 23 <sup>5</sup>Dept. of Pulmonary Medicine, Leiden University Medical Center, Leiden, Netherlands
- <sup>6</sup>Dept. of Immunology, Leiden University Medical Center, Leiden, Netherlands 24
- 25 <sup>7</sup>Dept. of Internal Medicine, Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, Netherlands 26
- <sup>8</sup>Dept. of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands 27
- 28 <sup>9</sup>Dept. of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands
- <sup>10</sup>Dept. of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands 29
- <sup>11</sup>Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands 30
- 31 <sup>12</sup>Dept. of Analytical Biosciences, Leiden Academic Centre for Drug Research, Leiden, Netherlands
- 32 <sup>13</sup>Dept. of Hematology, Leiden University Medical Center, Leiden, Netherlands
- 33 <sup>14</sup>Dept. of Parasitology, Leiden University Medical Center, Leiden, Netherlands
- 34 <sup>15</sup>Dept. of Human Genetics, Leiden University Medical Center, Leiden, Netherlands
- &COVID-19 group (in alphabetical order, investigators): 35
- M. Baysan<sup>2,3</sup>, M. G. J. de Boer<sup>4</sup>, A. G. van der Bom<sup>3</sup>, O. M. Dekkers<sup>3</sup>, A. M. Eikenboom<sup>3</sup>, S. B. ter 36
- Haar<sup>3</sup>, L. Heerdink<sup>3</sup>, L. J. van Heurn<sup>3</sup>, I. de Jonge<sup>3</sup>, W. Lijfering<sup>3</sup>, R. Meier<sup>1</sup>, J. A. Oud<sup>1</sup>, F. Rosendaal<sup>3</sup>, 37
- A. G. L. Toppenberg<sup>3</sup>, J. Uzorka<sup>4</sup>, A. A. van IJlzinga Veenstra, J. Wigbers<sup>2</sup>, J. M. Wubbolts<sup>4</sup> 38
- 39 <sup>1</sup>Dept. of Hematology, Leiden University Medical Center, Leiden, Netherlands
- 40 <sup>2</sup>Dept. of Intensive Care, Leiden University Medical Center, Leiden, Netherlands
- <sup>3</sup>Dept. of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands 41

#### 42 <sup>4</sup>Dept. of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands

- 43 **\*Correspondence:**
- 44 Tamas Pongracz
- 45 Albinusdreef 2, 2223ZA, Leiden, Netherlands
- 46 Tel: +31 71 526 8701
- 47 <u>t.pongracz@lumc.nl</u>

#### 48 Abstract

#### 49 Background

- 50 Immunoglobulin G1 (IgG1) effector functions are impacted by the structure of fragment crystallizable
- 51 (Fc) tail-linked *N*-glycans. Low fucosylation levels on severe acute respiratory syndrome coronavirus
- 52 2 (SARS-CoV-2) spike protein specific (anti-S) IgG1 has been described as a hallmark of severe
- 53 coronavirus disease 2019 (COVID-19) and may lead to activation of macrophages via immune
- 54 complexes thereby promoting inflammatory responses, altogether suggesting involvement of IgG1 Fc
- 55 glycosylation modulated immune mechanisms in COVID-19.

#### 56 Methods

- 57 In this prospective, observational single center cohort study, IgG1 Fc glycosylation was analyzed by
- 58 liquid chromatography mass spectrometry following affinity capturing from serial plasma samples
- 59 of 159 SARS-CoV-2 infected patients.

#### 60 Findings

- 61 At baseline close to disease onset, anti-S IgG1 glycosylation was highly skewed when compared to
- 62 total plasma IgG1. A rapid, general reduction in glycosylation skewing was observed during the disease

63 course. Low anti-S IgG1 galactosylation and sialylation as well as high bisection were early hallmarks

- of disease severity, whilst high galactosylation and sialylation and low bisection were found in patients
- 65 with low disease severity. In line with these observations, anti-S IgG1 glycosylation correlated with
- 66 various inflammatory markers.

## 67 Interpretation

- 68 Association of low galactosylation, sialylation as well as high bisection with disease severity suggests
- 69 that Fc-glycan modulated interactions contribute to disease mechanism. Further studies are needed to
- 70 understand how anti-S IgG1 glycosylation may contributes to disease mechanism and to evaluate its
- 71 biomarker potential.

#### 72 Funding

- 73 This project received funding from the European Commission's Horizon2020 research and innovation
- 74 program for H2020-MSCA-ITN IMforFUTURE, under grant agreement number 721815.

#### 75 Keywords: IgG glycosylation; anti-Spike IgG; SARS-CoV-2; COVID-19; coronavirus

- 76 **Research in context**
- 77 Evidence before this study

78 Antibody glycosylation against the spike (S) protein of patients infected with severe acute respiratory

79 syndrome SARS-CoV-2 has been reported as a potentially important determinant of COVID-19 80 disease severity. Studies have hitherto focused on afucosylation, a modification on immunoglobulin

G1 (IgG) Fc-tail-linked N-glycans that enhances effector functions. Most of these studies featured 81

limited sample numbers or were imperfectly matched with respect to demographic and other important 82

83 confounding factors. Our lab has contributed to some of these studies, and we additionally searched

84 for research articles on PubMed and Google Scholar from January 2020 to October 2021. To date, only 85

two groups studied anti-S IgG1 glycosylation, which resulted in overall three publications found. 86 However, none of these groups found a severity marker between hospitalized non-ICU and ICU

87 patients or studied dynamic changes. Instead, exclusively fucosylation at the first available timepoint

88 has been associated with disease severity between severely ill inpatients and mild outpatients.

#### 89 Added value of this study

90 In this prospective, observational single center cohort study, we investigated the severity marker

91 potential of anti-S IgG1 glycosylation in severe and mild hospitalized COVID-19 cases, and correlated

92 these findings with numerous inflammation and clinical markers. Our study reveals low galactosylation

93 and sialylation as well as high bisection on anti-S IgG1 as early hallmarks of severe COVID-19, after

94 correction for age and sex effects. In line with these observations, anti-S IgG1 glycosylation correlated

95 with many inflammatory markers. As days since onset is one of the major confounders of anti-S IgG1 96 glycosylation due to its highly dynamic nature, we additionally confirmed our findings in time-matched

97 patient subgroups. We believe anti-S IgG1 glycosylation may be applicable for patient stratification

98 upon hospitalization.

#### 99 Implications of all the available evidence

100 Demographic factors as well as temporal differences should be taken into consideration when 101 analyzing IgG1 glycosylation of COVID-19 patients. Anti-S IgG1 glycosylation is highly dynamic,

102 but is a promising early severity marker in COVID-19.

#### 103 1 Introduction

104 The current global coronavirus disease 19 (COVID-19) pandemic caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been leading to extensive

105

106 hospitalizations worldwide.<sup>1</sup> To date, more than 253 million infections and more than 5 million deaths

have been reported.<sup>2</sup> SARS-CoV-2 is an enveloped virus and its uptake by target cells in the respiratory 107

108 tract is mediated by the spike glycoprotein.<sup>1</sup> Interestingly, most infected people clear the virus with

109 mild symptoms, whilst around 20% of the adult cases are characterized by severe, sometimes life-

110 threatening conditions.<sup>3</sup> Approximately 7-10 days after symptom onset, seroconversion occurs with

111 immunoglobulin M (IgM) and A (IgA), and G (IgG) antibodies against the spike protein.<sup>4</sup> These 112 antibodies can form immune complexes with viral particles and thereby neutralize the virus and

113 mediate clearance, but are also capable of aggravating the disease.<sup>5-7</sup>

IgG exerts effector functions via the activation of complement or fragment crystallizable (Fc) gamma 114

- receptors (FcyR) on immune cells.<sup>8</sup> Various effector functions of IgG are steered by the *N*-glycan 115
- 116 moiety attached to the highly conserved N297 glycosylation sites within both C<sub>H</sub>2 domains of the Fc
- 117 tail.<sup>9,10</sup> Specifically, afucosylated IgG1 shows increased affinity to the activating FcyRIIIa receptor,
- hence leading to enhanced antibody-dependent cellular cytotoxicity (ADCC).<sup>10,11</sup> Galactosylated IgG1 118
- 119 shows increased hexamerization, C1q binding and complement activation.<sup>12</sup>

- 120 Recent reports have indicated that the high inter-individual variability in COVID-19 disease severity<sup>3</sup>
- 121 may partly be explained by low Fc fucosylation of anti-SARS-CoV-2 spike protein-specific (anti-S)
- IgG1. The lack of core fucose on these specific antibodies early on during disease points to their potential proinflammatory role in severe illness.<sup>6,13,14</sup> Literature suggests, that in particular membrane-
- 123 potential proinflammatory role in severe illness. Store Literature suggests, that in particular membrane-124 embedded foreign antigens, such as the SARS-CoV-2 spike protein, induce low fucosylated IgG1
- responses, which in combination with high titers may lead to excessive macrophage activation and
- drive COVID-19 associated pathology including acute respiratory distress syndrome.<sup>6,13</sup>
- 127 Here, we study the dynamics of IgG1 Fc glycosylation and its association with clinical parameters in
- 128 a longitudinal cohort of 159 hospitalized COVID-19 patients, analyzing a total of 1300 longitudinal
- 129 patient samples. We report on the association of early anti-S IgG1 glycosylation signatures with disease
- 130 severity and various inflammatory markers, indicating its biomarker potential.

## 131 **2** Methods

## 132 **2.1** Chemicals, reagents and enzymes

Type I Ultrapure Water was produced by an ELGA Purelab Ultra system (Elga LabWater, High 133 134 Wycombe, United Kingdom) and used to create solutions throughout. Ammonium bicarbonate, 135 potassium chloride, formic acid, tolylsulfonyl phenylalanyl chloromethyl ketone-treated trypsin from 136 bovine pancreas was obtained from Sigma-Aldrich (Steinheim, Germany). Trifluoroacetic acid, 137 disodium hydrogen phosphate dihydrate, potassium dihydrogen phosphate, and sodium chloride were purchased from Merck (Darmstadt, Germany). HPLC-supra-gradient acetonitrile was obtained from 138 139 Biosolve (Valkenswaard, The Netherlands). The Visucon-F pooled healthy human plasma standard 140 originated from Affinity Biologicals (Ancaster, Canada). Protein G Sepharose 4 Fast Flow beads were 141 obtained from GE Healthcare (Uppsala, Sweden). Recombinant trimerized spike protein was prepared 142 as described.<sup>15</sup>

## 143 **2.2 Study cohort**

144 BEAT-COVID-19 is a prospective, observational single center cohort study established at Leiden University Medical Center, with longitudinal plasma samples of 159 PCR-confirmed SARS-CoV-2 145 infected hospitalized patients that were collected during the first and second wave of the pandemic 146 147 (between May 2020 and October 2020) (Table 1, Table S1, Figure S1). After informed consent was 148 obtained from the patient or his/her relatives, longitudinal sampling was performed for the duration of 149 the hospital admission, and one convalescent sample was obtained at the outpatient follow-up 150 appointment, which was scheduled six weeks after hospital discharge. Statistical sample size 151 calculation was not performed, the sample size was determined based on availability. The Medical 152 Ethics Committee Leiden-Den Haag-Delft (NL73740.058.20) approved the study. The trial was 153 registered in the Dutch Trial Registry (NL8589). The study complied with the latest version of the 154 Declaration of Helsinki.

## 155 **2.3** Sample preparation for IgG Fc glycosylation analysis

156 Anti-S IgG was captured using a setup that resembles a conventional ELISA: IgGs were affinity-

157 captured from plasma using recombinant trimerized spike-protein-coated Maxisorp NUNC-Immuno

- 158 plate (Thermo Fisher Scientific, Roskilde, Denmark), whereas total IgG was affinity-captured using
- protein G Sepharose Fast Flow 4 beads, as described previously.<sup>13,16</sup> Antibodies were eluted using 100
- 160 mM formic acid and the samples were dried by vacuum centrifugation. Samples were reconstituted in 161 25 mM ammonium bicarbonate and subjected to truptic cleavage, as described elsewhere <sup>16</sup> Samples
- 161 25 mM ammonium bicarbonate and subjected to tryptic cleavage, as described elsewhere.<sup>16</sup> Samples

162 belonging to a single patient were prepared and measured consecutively on the same plate, except for

163 follow-up samples after hospitalization period. On each plate, at least 3 Visucon-F plasma standards

164 (dating pre-COVID-19) and 3 blanks were included.

## 165 **2.4 IgG Fc glycosylation analysis**

166 Glycopeptides were separated and detected using an Ultimate 3000 high-performance liquid 167 chromatography (HPLC) system (Thermo Fisher Scientific, Waltham, MA) hyphenated to an Impact 168 quadrupole time-of-flight mass spectrometer (Bruker Daltonics, Billerica, MA), as described.<sup>16</sup>

## 169 **2.5** Liquid chromatograph – mass spectrometry data processing

170 MzXML files were generated from raw liquid chromatograph – mass spectrometry (LC-MS) spectra. 171 An in-house developed software, LaCyTools was used for the alignment and targeted extraction of raw data.<sup>17</sup> Alignment was performed based on the average retention time of minimum three abundant IgG1 172 173 glycoforms. The targeted extraction list included analytes of the  $2^+$  and  $3^+$  charge states and was based on manual annotation of the mass spectra as well as on literature.<sup>18,19</sup> A pre-COVID-19 plasma pool 174 175 (Visucon-F) was measured in triplicate in each plate to assess method robustness and was as well used 176 as negative control. All spectra below the average intensity plus three times the standard deviation of 177 negative controls was excluded from further analysis. Signals were integrated by covering a minimum 178 of 95% of the area of the isotopic envelope of glycopeptide peaks. Inclusion of an analyte for the final 179 data analysis was based on quality criteria such as signal-to-noise (>9), isotopic pattern quality (< 25%180 deviation from the theoretical isotopic pattern), and mass error (within  $a \pm 20$  ppm range). Furthermore, 181 analytes that were present in at least 1 out of 4 anti-S IgG1 spectra (25%) were included in the final

analysis.

## 183 **2.6** Cytokine measurements by cytometric bead array

184 Circulating cytokine and chemokine levels were determined in serum using commercially available 185 bead based multiplex assays using the BioPLex 100 system for acquisition as previously described.<sup>20</sup> 186 Standard curves were included in the kits and, in addition, a pooled serum sample of 4 hospital admitted 187 COVID-19 patients was included as internal reference in all assays. Four commercially available kits were used: Bio-Plex Pro<sup>TM</sup> Human Cytokine Screening Panel 48-plex, Bio-Plex Pro<sup>tm</sup> Human 188 Chemokine Panel 40-Plex, Bio-Plex Protim Human Inflammation Panel 1 and 37-Plex; Bio-Plex Protim 189 190 Human Th17 panel (IL-17F, IL-21, IL-23, IL-25, IL-31, IL-33) (all obtained from Bio-Rad, Veenendaal, The Netherlands). 191

## 192 2.7 Antibody titer measurement

Semi-quantitative detection of SARS-CoV-2 anti-nucleocapsid (N) protein IgG was performed on the Abbott Architect platform.<sup>21-23</sup> In this antibody chemiluminescent microparticle immunoassay (CMIA) test, the SARS-CoV-2 antigen coated paramagnetic microparticles bind to the IgG antibodies that attach to the viral nucleocapsid protein in human serum samples. The Sample/Calibrator index values of chemiluminescence in relative light units (RLU) of 1.40 (IgG assay) respectively 1.00 (IgM assay) and above were considered as positive per the manufacturer's instructions.

Quantitative detection of SARS-CoV-2 anti-S1/S2 IgG antibodies was performed using the DiaSorin
 LIAISON platform. The CLIA assay consists of paramagnetic microparticles coated with distally
 biotinylated S1 and S2 fragments of the viral surface spike protein. RLUs proportional to the sample's
 anti-S1/S2 IgG levels are converted to AU/mL based on a standardized master curve.

Semi-quantitative detection of SARS-CoV-2 anti-RBD IgM antibodies was performed using the Wantai IgM-ELISA (CE-IVD) kit (Sanbio).<sup>24</sup> Briefly, the IgM u-chain capture method was used to detect IgM antibodies using a double-antigen sandwich immunoassay using mammalian cell-expressed recombinant antigens containing the RBD of the spike protein of SARS-CoV-2 and the immobilized and horseradish peroxidase-conjugated antigen. Sample/Cut-off index OD values of 1 and higher were considered positive per the manufacturer's instructions.

209 Semi-quantitative detection of SARS-CoV-2 anti-S1 IgA antibodies was performed using the 210 Euroimmun IgA 2-step ELISA.<sup>25</sup> Ratio values of  $1 \cdot 1$  and higher were considered positive per the 211 manufacturer's instructions.

## 212 **2.8 Severity score calculation**

The severity score is based on the 4C mortality score.<sup>26</sup> The 4C mortality score is a prediction score calculated at admission, and the severity score calculated in our cohort represents the daily clinical

disease severity, and thus is dependent on parameters that can change over time. Therefore, the fixed

216 parameters of the 4C score were removed (i.e. age, sex at birth, number of comorbidities. Daily oxygen 217 flow for non ICU patients ( $I_{1}$  (min) and p(f ratio ( $I_{2}$  Ref)) and EiO2 ( $I_{2}$ ) for ICU patients were added to our

flow for non-ICU patients (L/min) and p/f ratio (kPa) and FiO2 (%) for ICU patients were added to our

218 severity score (**Table S2**).

## 219 2.9 Statistical analysis

220 Relative intensity of each glycopeptide species in the final analyte list was calculated by normalizing 221 to the sum of their total areas (Table S3). Structurally similar glycopeptide species were used for the 222 calculation of derived traits fucosylation, bisection, galactosylation and sialylation (Table S4). Anti-S 223 and total IgG1 glycosylation traits were compared using a Wilcoxon signed-rank test (Figure 1, Table 224 **S5**), while a Wilcoxon rank-sum test was used to compare non-ICU and ICU patients as well as severity 225 score groups (Figure 3-4; Table S6-7; Figure S3, Figure S9-10). To account for multiple testing, p-226 values of the Wilcoxon-tests have been corrected by the Benjamini-Hochberg procedure to 5% FDR 227 in each statistical question (Table S5-7). Spearman's correlation was used to explore associations 228 between glycosylation traits and age (Figure S2), as well as between glycosylation traits and 229 inflammatory markers and titers (Figure 5, Table S8). To assess method repeatability, the inter-plate 230 variation for the 14 analytes included in the final analysis was calculated for the standards, which was 231 2.4%. All statistical analyses and visualizations were performed in R, version 4.1.0 (R Foundation for

232 Statistical Computing, Vienna, Austria) and RStudio, version 1.4.1717 (RStudio, Boston, MA).

## 233 **2.10 Role of funding source**

The funders had no role in study design, data collection, data analysis, data interpretation, or writingof the report.

## 236 **3 Results**

Both anti-S and total IgG1 glycosylation signature of 159 COVID-19 patients (39 female and 119 male) and corresponding timepoints were analyzed during their entire hospitalization period. The patient demographics and the comprehensive cohort characteristics are presented in **Table 1** and **Table S1**, respectively. Follow-up samples after hospital discharge were available for 19 patients (**Table S1**, **Figure S5**). LC-MS was employed to analyze Fc glycosylation on the glycopeptide level after tryptic digestion, which allowed the identification of 14 glycoforms. The found glycoforms were consistent with previous reports on anti-S IgG1 glycosylation<sup>13,14</sup>, from which fucosylation, bisection,

- 244 galactosylation and sialylation were calculated (Table S3-4). Overall, a total of 650 total IgG1 and 650
- anti-S IgG1 glycosylation profiles were determined.

Table 1. Baseline patient characteristics. Median and interquartile ranges are shown unless indicated otherwise. The sex
 of one patient is unknown (not shown).

	ICU (n=77)	non-ICU (n=82)
Age	65 (59-71)	66.5 (54-74.5)
Female, n (%)	18 (23)	21 (26
Male, n (%)	59 (77)	60 (74)
Severity score	12 (10-14)	3 (2-4)
Days since symptom onset	15.5 (12-22)	13 (10-16)

## 248 3.1 Anti-S IgG1 Fc glycosylation of COVID-19 patients is skewed

249 The Fc glycosylation signatures of anti-S and total IgG1 were compared pairwise at hospitalization 250 with regard to fucosylation, bisection, galactosylation and sialylation (Figure 1, Table S5). Fucosylation of anti-S was significantly lower than total (fold change (FC): 0.93; *p*-value:  $3.4 \times 10^{-24}$ ) 251 252 (Figure 1A, Table S5). Notably, a prominently low anti-S fucosylation (<85%) was found for 56 253 patients, with a few patients showing levels as low as 66% (Figure 1A). Similarly, bisection of anti-S was markedly lower than total IgG1 (FC: 0.33; *p*-value:  $3.1 \times 10^{-27}$ ) (Figure 1B). Anti-S galactosylation 254 (FC: 1.35; *p*-value:  $8.1 \times 10^{-26}$ ) (Figure 1C) and sialylation (FC: 1.45; *p*-value:  $2.7 \times 10^{-26}$ ) (Figure 1D) 255 256 were elevated as compared to their total IgG1 counterpart.



Figure 1. Comparison of anti-S (blue) and total (yellow) IgG1 Fc glycosylation. Relative abundance of IgG1 (A)
 fucosylation, (B) bisection, (C) galactosylation and (D) sialylation of anti-S and total IgG1 are given at hospitalization
 (n=159). Boxplots display the median and the interquartile range, whereas whiskers represent the first and third quartiles.
 A Wilcoxon signed-rank test was used to compare anti-S with total IgG1. \*\*\*\*: p-value < 0.0001.</li>

## 262 **3.2 Dynamic regulation of IgG1 Fc glycosylation in COVID-19**

263 Next, we explored the changes of glycosylation over time. Anti-S glycosylation was found to be highly

264 dynamic, but also total IgG1 glycosylation showed changes in the course of the disease (Figure S6).

265 Both anti-S and total IgG1 galactosylation was found to be confounded by age and sex (Figure S2) in

266 line with literature on IgG Fc glycosylation.<sup>27</sup> Therefore, delta ( $\Delta$ ) values were calculated by

267 subtracting total from anti-S IgG1 levels to eliminate the confounding effect, and used hereafter

268 (**Figure S2-3**).



Figure 2. ΔGlycosylation dynamics until 60 days since symptom onset. The time course of Δglycosylation traits (A)
 fucosylation, (B) galactosylation, (C) bisection and (D) sialylation as shown during the hospitalization period (n=109). Line
 colors correspond to a single COVID-19 patient, whilst the color gradient in the circles/squares indicate the corresponding
 severity score (grey = NA). The shape displays whether a patient passed away (square) or was discharged alive (circle).
 The black dashed line with a grey 95% confidence interval band is a cubic polynomial fit over the shown datapoints to
 illustrate overall dynamics. Late timepoints and two outliers are shown in the Supplementary Material due to spatial
 constraints (Figure S4-5), as well as anti-S and total IgG1 glycosylation dynamics (Figure S6).

277 The longitudinal samples allowed us to establish the time course of  $\Delta IgG1$  glycosylation during 278 hospitalization, normalized for day of onset of symptoms (Figure 2, Table S1). Interestingly, all 279 glycosylation traits showed a transient pattern for most patients, and were characterized by profound 280 dynamics, as illustrated by the timelines of individual patients (as indicated by differential line 281 coloring) and by the fit cubic polynomial line (Figure 2). Fucosylation (Figure 2A) and bisection 282 (Figure 2C) showed a rapid increase within days and weeks after onset of the disease, followed by a 283 plateau and approximation of the glycosylation patterns of total IgG1 (Figure S6). In contrast, 284 galactosylation (Figure 2B) and sialylation (Figure 2D) quickly declined in the first days and weeks, 285 with the decrease continuing for a long period albeit at lower pace. At the moment of hospital discharge 286 anti-S galactosylation and sialylation were still slightly higher than total IgG1. Since 19 patients 287 returned for follow-up sampling after hospital discharge, we noted that for most, fucosylation and 288 bisection largely remained constant or slightly increased, whilst galactosylation and sialylation 289 continued to decrease since the last available timepoint (Figure S5).

#### 290 **3.3 IgG1 Fc glycosylation associates with ICU admission**

To investigate whether Fc glycosylation was associated with intensive care unit (ICU) admission, patients were stratified based on treatment need. This resulted in two groups: 1) patients who at some point during hospitalization were admitted to the ICU, and 2) patients who were not enrolled to ICU treatment at all (non-ICU) during hospitalization.  $\Delta$ IgG1 glycosylation derived traits fucosylation, bisection, galactosylation and sialylation of the above groups were compared both at time of hospitalization and at the time point of their highest disease severity (**Figure 3, Table S6**).

medRxiv preprint doi: https://doi.org/10.1101/2021.11.18.21266442; this version posted November 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

![](_page_9_Figure_1.jpeg)

297 (O' (O' (O'))
298 Figure 3. Comparison of Aglycosylation traits of patients admitted to ICU (red) or non-ICU (blue) treatment. Shown
299 in the facets are the relative levels of ΔIgG1 (A) fucosylation, (B) galactosylation, (C) bisection and (D) sialylation at the
200 time of hospitalization (left; n=159; 77 ICU and 82 non-ICU patients, respectively) and at the time of highest disease
201 severity (right; n=144; 75 ICU and 69 non-ICU patients, respectively). The highest severity timepoint has been defined for
202 each patient as the earliest possible timepoint with highest severity score during hospitalization. A Wilcoxon rank-sum test
203 was used to compare ICU and non- ICU patients (Table S6). \*, \*\*\*\*: p-value < 0.05, 0.0001, respectively. Glycosylation</li>
204 dynamics of ICU and non-ICU patients between day 10 and 25 are shown in Figure S8.

305  $\Delta$ IgG1 Fc glycosylation of ICU patients showed a different profile from those of non-ICU patients, with the latter being characterized by lower bisection (FC: 0.66, *p*-value:  $7.2 \times 10^{-8}$ ) (Figure 3C), and 306 higher galactosylation (FC: 0.39, *p*-value:  $2.9 \times 10^{-9}$ ) (Figure 3B) and sialylation (FC: 0.46, *p*-value: 307  $1.7 \times 10^{-7}$ ) at the time of hospitalization (Figure 3D). This difference was maintained or even more 308 309 pronounced at the time of highest disease severity (FC: 0.61, 0.26, 0.34; *p*-value:  $1.9 \times 10^{-10}$ ,  $4.1 \times 10^{-10}$ <sup>12</sup>,  $3.4 \times 10^{-9}$ , for  $\Delta$  bisection,  $\Delta$  galactosylation and  $\Delta$  sialylation, respectively) (**Table S6**). Fucosylation 310 311 levels of the ICU group were higher at the time of highest disease severity (FC 0.62; p-value: 0.012), 312 but remained similar at the time of hospital admission (Figure 3A). To confirm that the observed 313 effects were not confounded by vast glycosylation dynamics, a subset of non-ICU and ICU patients 314 were created and compared, which resulted in comparable observations with regards to  $\Delta$ bisection, 315  $\Delta$ galactosylation and  $\Delta$ sialylation as shown above (Figure S7-8).

#### 316 3.4 IgG1 Fc glycosylation associates with disease severity

317 Patients were stratified into three groups based on their severity score: 1) severity score between 0-5

(low severity), 2) 6-11 (intermediate severity) and 3) 12-17 (high severity). Similarly as before,  $\Delta IgG1$ 

319 glycosylation traits were compared both at time of hospitalization and at time of highest disease

320 severity (Figure 4, Table S7).

![](_page_10_Figure_5.jpeg)

321

Figure 4. Comparison of Aglycosylation of patients in different severity score groups. Shown in the facets are the relative levels of ΔIgG1 (A) fucosylation, (B) bisection, (C) galactosylation and (D) sialylation at the time of hospitalization (left; n=142; 64 low severity, 32 intermediate severity and 46 high severity patients, respectively) and at the time of highest disease severity (right; n=144 n=144; 61 low severity, 24 intermediate severity and 59 high severity patients, respectively).
 Color indicates ICU (red) and non-ICU (blue) patients. A Wilcoxon rank-sum test was used to compare the different severity score groups (Table S7). \*, \*\*, \*\*\*\*: p-value < 0.05, 0.01, 0.0001, respectively.</li>

 $\Delta$ Bisection was found to be increased in groups with increased disease severity (**Figure 4C**), whereas  $\Delta$ galactosylation (**Figure 4B**) and  $\Delta$ sialylation (**Figure 4D**) patterns were found to be decreased with increased disease severity at the time of hospitalization (**Table S7**). These observations were largely

331 maintained at highest disease severity (Figure 4, Table S7). Higher fucosylation marked the time of

332 highest disease severity, but remained rather stable at the time of hospital admission between all groups

333 (Figure 4A, Table S7). To confirm that the observed effects were not confounded due to profound

334 glycosylation dynamics, subsets of patients matched for the time since disease onset were compared,

335 which resulted in similar observations with regards to  $\Delta$ galactosylation and  $\Delta$ sialylation as shown

above, whereas we could not exclude a potential confounding effect for the bisection signature, maybe

caused by swift glycosylation dynamics, low sample size, or the combination thereof (Figure S9).

Apart from ICU admission and severity score, we tested acute respiratory syndrome, ventilation and survival, and found  $\Delta$ bisection being higher for patients at baseline who passed away later (**Figure** 

340 **S10**).

#### 341 **3.5** IgG1 Fc glycosylation associates with inflammatory markers

342 Multiple inflammatory mediators (in serum) and clinical parameters were measured for patients 343 enrolled during the first wave of the pandemic. These include members of the CXC, CCL and CX3C 344 chemokine families, cytokines and corresponding soluble receptors, acute phase proteins and other 345 mediators involved in the immune response as well as severity scores and anti-viral antibody titers. In 346 general, negative associations were found between  $\Delta$ galactosylation and  $\Delta$ sialylation and positive 347 associations for  $\Delta$ bisection and  $\Delta$ fucosylation with inflammatory markers at baseline. One notable 348 exception was a strong negative correlation between anti-RBD IgM levels and  $\Delta$ bisection and 349  $\Delta$  fucosylation at baseline and at highest severity, respectively.  $\Delta$  Sialylation associated negatively with 350 various chemokines, such as CCL24 (r = -0.45), CX3CL1 (r = -0.43), CCL25 (r = -0.34), certain

351 cytokines, such as IL-8 (r = -0.29), IFN- $\gamma$  (r = -0.3) and several other variables (**Figure 5, Table S8**).

![](_page_12_Figure_1.jpeg)

Figure 5. Heatmap visualizing Spearman's correlations between Δglycosylation traits and inflammatory markers at time of hospitalization (left side of each panel; n=58) and at time of highest disease severity (right side of each panel;

time of hospitalization (left side of each panel; n=58) and at time of highest disease severity (right side of each panel;
 n=59). Asterisk (\*) indicates a significant Spearman's correlation (*p*-value < 0.05).</li>

356 Comparable, and largely overlapping negative associations were found for  $\Delta$ galactosylation as for 357  $\Delta$ sialylation: CCL24 (r = -0.55), CX3CL1 (r = -0.56), CCL25 (r = -0.41), IL-8 (r = -0.44), INF- $\gamma$  (r = 358 -0.4) and TNF- $\beta$  (r = -0.33). Conversely,  $\Delta$  bisection associated positively with IL-8 (r = 0.56), CCL25 (r = 0.52) and CX3CL1 (r = 0.56). Additionally, severity score negatively correlated with 359 360  $\Delta$ galactosylation (r = -0.55) and  $\Delta$ sialylation (r = -0.41) and positively with  $\Delta$ bisection (r = 0.46). Positive associations were found between  $\Delta$  fucosylation and inflammatory markers, including CCL17 361 362 (r = 0.41) and IL-8 (r = 0.34). The above described baseline correlations were comparable to those at the time of highest disease severity, but a vast body of associations were temporary (Figure 5, Table 363 364 **S8**).

#### 365 4 Discussion

In this study, we analyzed total and anti-S IgG1 Fc glycosylation of 159 COVID-19 patients at different timepoints during their clinical illness. Although several studies reported on the importance of (anti-S) IgG1 Fc glycosylation and its association with disease severity in COVID-19<sup>6,13,14,28,29</sup>, this study involves a large, single center cohort that confirms specific anti-S IgG1 glycosylation features as an early hallmark of severe COVID-19 in an age- and sex-corrected, time-matched dataset at baseline, and in the longitudinal dimension.

372 Afucosylated IgG1 B cell responses have recently been described to characterize immune reactions 373 against membrane-embedded antigens in general, and in particular against viral infections caused by enveloped viruses such as COVID-19.<sup>13</sup> Foregoing studies showed that severe, hospitalized patients 374 exhibit a decreased anti-S IgG1 fucosylation as compared to mild, non-hospitalized patients.<sup>6,13,14</sup> 375 376 Accordingly, we likewise observed proinflammatory, low-fucosylation signatures on anti-S as 377 compared to total IgG1, but found no difference in fucosylation comparing hospitalized ICU patients 378 versus hospitalized non-ICU patients, which is in line with a previous report on anti-SARS-CoV-2 receptor binding domain (anti-RBD) IgG1 fucosylation.<sup>14</sup> Therefore, based on the early existence of 379 these proinflammatory signatures in some of the patients, we hypothesize that low fucosylation -380 potentially even lower before measurable seroconversion, as hypothesized before  $^{13}$  – on anti-S IgG1 381 382 may act as an early inflammatory signal that promotes the development of a more severe disease in 383 COVID-19 patients, resulting in hospital admission. However, disease severity between hospitalized 384 patients could not be further distinguished based on anti-S IgG1 fucosylation. Furthermore, hardly any 385 negative associations were found between anti-S IgG1 fucosylation and inflammatory markers in this 386 study, unlike in previous reports, where in vitro experiments demonstrated that the stimulation of 387 isolated macrophages with recombinant, glycoengineered anti-S or patient sera-derived low-fucose 388 IgG1 antibodies trigger higher proinflammatory cytokine release than those with normal fucose levels.<sup>6,13,14</sup> However, high proinflammatory cytokine levels are not necessarily present in all severe 389 390 patients<sup>30</sup>, and this contrasting observation suggests a different regulation and/or the temporal 391 resolution of fucosylation and cytokine production dynamics in vivo. Additionally, beyond or in 392 combination with low anti-S IgG1 fucosylation a pre-existing risk factor may plays a role in COVID-19 disease severity, which hitherto remained unclear.<sup>29</sup> Of note, the anti-S and anti-RBD IgG1 Fc 393 394 glycosylation data were all determined from the circulation, and it is unclear to which extent this would 395 reflect the inflammatory pattern and glycosylation profile of anti-S antibodies in the lung. Our results 396 demonstrate that the proinflammatory fucosylation signature that is observed at the early time points 397 in the disease tends to fade with the course of the disease, which one may interpret as a shift towards a 398 more anti-inflammatory Fc glycosylation profile that is maintained over time. The absence of core

399 fucose is known to enhance a proinflammatory immune response by activating FcyRIII receptors on monocytes, macrophages and NK cells.<sup>10</sup> Decreased fucosylation on specific IgG1 has been described 400 in HIV<sup>13,31</sup> and dengue fever<sup>32</sup>, as well as in alloimmune diseases.<sup>33-37</sup> However, whilst afucosylation 401 of specific IgG1 plays a protective role in HIV, it clearly marks high disease severity in dengue, 402 alloimmune diseases or COVID-19.6,13,14 Furthermore, low total IgG1 fucosylation has been associated 403 with outcome of pediatric meningococcal sepsis indicating a systemic inflammation due to the potential 404 accumulation of airway infections during early childhood.<sup>38</sup> Even though the origin of low fucose IgG 405 responses is seemingly linked to antigen context and affect mostly specific antibodies<sup>13</sup>, the 406 407 mechanisms underlying the dynamics of antibody glycosylation remain elusive.

Besides afucosylation, a transient, decreased bisection was found on anti-S IgG1. Recent reports
suggest that severe COVID-19 patients present low levels of bisection both on total IgG (Fc and Fab
combined)<sup>29</sup> and anti-S IgG1<sup>13</sup> relative to mild cases. In contrast, no difference was found in anti-RBD
IgG1 bisection between ICU and non-ICU patients in age- and sex-matched patients<sup>14</sup>, albeit these
disease groups were largely comparable to the ones in our study. While bisection associated positively
with ICU admission, disease severity and survival in our study, it lacks functional relevance based on
our current understanding and has no effect on FcγRIII or C1q binding.<sup>10,39</sup>

415 Elevated galactosylation and sialylation of anti-S IgG1 were associated with a less severe disease 416 course upon hospitalization, and no ICU admission. Similar observations were made in a previous 417 report, where severe COVID-19 was characterized by lower anti-S IgG1 galactosylation and sialylation than mild COVID-19.<sup>13</sup> Interestingly, both anti-S and total IgG1 galactosylation and sialylation 418 419 decrease by advancing age. As Larsen et al. compared anti-S IgG1 galactosylation and sialylation of 420 imperfectly age matched patient groups without age correction, the disease and age effects remained indiscernible.<sup>13</sup> We describe decreased anti-S IgG1 galactosylation in ICU patients as compared to 421 422 non-ICU patients, and analogously, markedly lower specific IgG1 galactosylation has been shown to 423 characterize the more severe, active phase of tuberculosis as compared to its latent counterpart.<sup>40</sup> Even though more and more reports support that elevated levels of galactosylated IgG are associated with 424 the activation of the classical complement pathway<sup>10,12,41</sup>, galactosylation was associated with 425 426 increased disease severity in this study, possibly due to the fact that complement can contribute to the 427 increased inflammation both directly, and through inducing a chemotactic response through C5a, 428 thereby increasing cellular infiltration to inflamed tissues such as the lung.<sup>42</sup> Elevated sialylation levels 429 on anti-S IgG1 were associated with increased disease severity in the current report. Sialylation has been broadly described as critical in mediating anti-inflammatory activity<sup>43-45</sup>, yet it remains to be 430 431 elucidated whether sialylated IgG exerts an anti-inflammatory effect in COVID-19.

## 432 **5** Conclusions

This study established anti-S IgG1 bisection, galactosylation and sialylation as a unique combination
of features that associate with ICU admission and disease severity in hospitalized COVID-19 patients.
These features were additionally associated with markers of inflammation. Hence, we believe anti-S
IgG1 glycosylation may be applicable for patient stratification upon hospitalization. The glycosylation
profiles are highly dynamic, the drivers of which remain elusive and to be investigated in future studies.

## 438 6 Contributors

T. P.: Data (pre)processing, data curation, formal analysis, validation, investigation, visualization,
statistical analysis, data interpretation, conceptualization, writing – original draft preparation. J. N.:
sample preparation, data acquisition (IgG Fc glycosylation), W. W.: sample preparation (IgG Fc

- 442 glycosylation), F. L.: production and purification of recombinant spike protein, K. E. van M, S. A. J.,
- 443 T. H. M. O: data acquisition (soluble marker profiles), review J. J. C. V.: data acquisition (antibody 444 titers), writing – review & editing, A. H. E. R., S. M. A.: set up of cohort, recruitment & sampling of
- 444 titlers), writing review & editing, A. H. E. K., S. M. A.: set up of conort, recruitment & sampling of 445 participants, writing – review & editing, G.V., C. H. H.: writing – reviewing & editing M. W.:
- 446 Supervision, writing review & editing, conceptualization, funding acquisition.
- 447 All authors were involved in the critical revision of the manuscript and have given approval to the final448 version of the manuscript.

## 449 **7 Declaration of interests**

A. H. E. R received support from Crowdfunding Wake Up To Corona, organized by the Leiden
University Fund, participated in grants or contracts with Diorapthe, Stichting apothekers and UNeedle,
participated on a Data Safety Monitoring/Advisory Board of a multicenter Dutch clinical trial (Clinical
trial (RCT) on convalescent plasma for treatment of immunocompromised patients with COVID-19)
and has recently been appointed as member of the EMA scientific advisory group on vaccines (unpaid).

The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## 457 **8 Funding**

This project received funding from the European Commission's Horizon2020 research and innovation program for H2020-MSCA-ITN IMforFUTURE, under grant agreement number 721815, and supported by Crowdfunding Wake Up To Corona, organized by the Leiden University Fund.

## 461 9 Data sharing

462 The datasets generated for this study are available on request from the corresponding author.

## 463 **10 References**

- 464 1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus
  465 of probable bat origin. *Nature* 2020; **579**(7798): 270-3.
- 466 2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
  467 time. *The Lancet Infectious Diseases* 2020; **20**(5): 533-4.
- 468 3. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative
  469 Review. Ann Intern Med 2020; 173(5): 362-7.
- 470 4. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with 471 COVID-19. *Nat Med* 2020; **26**(6): 845-8.
- 472 5. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev*473 *Microbiol* 2021; **19**(3): 141-54.
- 474 6. Hoepel W, Chen HJ, Geyer CE, et al. High titers and low fucosylation of early human anti475 SARS-CoV-2 IgG promote inflammation by alveolar macrophages. *Sci Transl Med* 2021; 13(596).
- 476 7. Ankerhold J, Giese S, Kolb P, et al. Circulating multimeric immune complexes drive
  477 immunopathology in COVID-19. *bioRxiv* 2021.

- 8. Bruhns P, Jonsson F. Mouse and human FcR effector functions. *Immunol Rev* 2015; 268(1):
  25-51.
- 480 9. Lauc G, Pezer M, Rudan I, Campbell H. Mechanisms of disease: The human N-glycome.
  481 *Biochim Biophys Acta* 2016; **1860**(8): 1574-82.
- 482 10. Dekkers G, Treffers L, Plomp R, et al. Decoding the Human Immunoglobulin G-Glycan
  483 Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities. *Front*484 *Immunol* 2017; 8: 877.
- 485 11. Ferrara C, Grau S, Jager C, et al. Unique carbohydrate-carbohydrate interactions are required
  486 for high affinity binding between FcgammaRIII and antibodies lacking core fucose. *Proc Natl Acad*487 Sci U S A 2011; 108(31): 12669-74.
- 488 12. van Osch TLJ, Nouta J, Derksen NIL, et al. Fc Galactosylation Promotes Hexamerization of
  489 Human IgG1, Leading to Enhanced Classical Complement Activation. *J Immunol* 2021; **207**(6): 1545490 54.
- 491 13. Larsen MD, de Graaf EL, Sonneveld ME, et al. Afucosylated IgG characterizes enveloped viral
  492 responses and correlates with COVID-19 severity. *Science* 2021; **371**(6532).
- 493 14. Chakraborty S, Gonzalez J, Edwards K, et al. Proinflammatory IgG Fc structures in patients
  494 with severe COVID-19. *Nat Immunol* 2021; 22(1): 67-73.
- 495 15. Brouwer PJM, Caniels TG, van der Straten K, et al. Potent neutralizing antibodies from
  496 COVID-19 patients define multiple targets of vulnerability. *Science* 2020; **369**(6504): 643-50.
- 497 16. Falck D, Jansen BC, de Haan N, Wuhrer M. High-Throughput Analysis of IgG Fc
  498 Glycopeptides by LC-MS. *Methods Mol Biol* 2017; **1503**: 31-47.
- 499 17. Jansen BC, Falck D, de Haan N, et al. LaCyTools: A Targeted Liquid Chromatography-Mass
  500 Spectrometry Data Processing Package for Relative Quantitation of Glycopeptides. *J Proteome Res*501 2016; **15**(7): 2198-210.
- Pucic M, Knezevic A, Vidic J, et al. High throughput isolation and glycosylation analysis of
   IgG-variability and heritability of the IgG glycome in three isolated human populations. *Mol Cell Proteomics* 2011; **10**(10): M111 010090.
- 505 19. Clerc F, Reiding KR, Jansen BC, Kammeijer GS, Bondt A, Wuhrer M. Human plasma protein
  506 N-glycosylation. *Glycoconj J* 2016; **33**(3): 309-43.
- van Meijgaarden KE, Khatri B, Smith SG, et al. Cross-laboratory evaluation of multiplex bead
  assays including independent common reference standards for immunological monitoring of
  observational and interventional human studies. *PLoS One* 2018; **13**(9): e0201205.
- 510 21. Escribano P, Alvarez-Uria A, Alonso R, et al. Detection of SARS-CoV-2 antibodies is 511 insufficient for the diagnosis of active or cured COVID-19. *Sci Rep* 2020; **10**(1): 19893.
- 512 22. Maine GN, Lao KM, Krishnan SM, et al. Longitudinal characterization of the IgM and IgG
  513 humoral response in symptomatic COVID-19 patients using the Abbott Architect. *Journal of Clinical*514 *Virology* 2020; 133.
- 515 23. Zlei M, Sidorov IA, Joosten S, et al. Absence of rapid T cell control corresponds with delayed 516 viral clearance in hospitalised COVID-19 patients. *ResearchSquare* 2021.
- 517 24. Zhao J, Yuan Q, Wang H, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel
  518 Coronavirus Disease 2019. *Clin Infect Dis* 2020; **71**(16): 2027-34.

- 519 25. Beavis KG, Matushek SM, Abeleda APF, et al. Evaluation of the EUROIMMUN Anti-SARS-520 CoV-2 ELISA Assay for detection of IgA and IgG antibodies. *J Clin Virol* 2020; **129**: 104468.
- 521 26. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-522 19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C 523 Mortality Score. *BMJ* 2020; **370**: m3339.
- 524 27. Kristic J, Vuckovic F, Menni C, et al. Glycans are a novel biomarker of chronological and 525 biological ages. *J Gerontol A Biol Sci Med Sci* 2014; **69**(7): 779-89.
- 526 28. Bye AP, Hoepel W, Mitchell JL, et al. Aberrant glycosylation of anti-SARS-CoV-2 IgG is a 527 pro-thrombotic stimulus for platelets. *Blood* 2021; **138**(16): 1481-9.
- 528 29. Petrovic T, Alves I, Bugada D, et al. Composition of the immunoglobulin G glycome associates 529 with the severity of COVID-19. *Glycobiology* 2021; **31**(4): 372-7.
- S30 30. Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine Levels in Critically III
  Patients With COVID-19 and Other Conditions. *JAMA* 2020; **324**(15): 1565-7.
- Ackerman ME, Crispin M, Yu X, et al. Natural variation in Fc glycosylation of HIV-specific
  antibodies impacts antiviral activity. *J Clin Invest* 2013; **123**(5): 2183-92.
- 534 32. Wang TT, Sewatanon J, Memoli MJ, et al. IgG antibodies to dengue enhanced for 535 FcgammaRIIIA binding determine disease severity. *Science* 2017; **355**(6323): 395-8.
- 536 33. Kapur R, Della Valle L, Sonneveld M, et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy:
  a new variable predicting severity in haemolytic disease of the fetus and newborn. *Br J Haematol* 2014;
  538 166(6): 936-45.
- 539 34. Kapur R, Kustiawan I, Vestrheim A, et al. A prominent lack of IgG1-Fc fucosylation of platelet 540 alloantibodies in pregnancy. *Blood* 2014; **123**(4): 471-80.
- 541 35. Sonneveld ME, de Haas M, Koeleman C, et al. Patients with IgG1-anti-red blood cell 542 autoantibodies show aberrant Fc-glycosylation. *Sci Rep* 2017; **7**(1): 8187.
- 543 36. Sonneveld ME, Koelewijn J, de Haas M, et al. Antigen specificity determines anti-red blood 544 cell IgG-Fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and 545 newborn. *Br J Haematol* 2017; **176**(4): 651-60.
- 546 37. Sonneveld ME, Natunen S, Sainio S, et al. Glycosylation pattern of anti-platelet IgG is stable
  547 during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia. *Br J Haematol*548 2016; **174**(2): 310-20.
- 549 38. de Haan N, Boeddha NP, Ekinci E, et al. Differences in IgG Fc Glycosylation Are Associated 550 with Outcome of Pediatric Meningococcal Sepsis. *mBio* 2018; **9**(3).
- 551 39. Thomann M, Schlothauer T, Dashivets T, et al. In vitro glycoengineering of IgG1 and its effect 552 on Fc receptor binding and ADCC activity. *PLoS One* 2015; **10**(8): e0134949.
- 40. Lu LL, Das J, Grace PS, Fortune SM, Restrepo BI, Alter G. Antibody Fc Glycosylation
  Discriminates Between Latent and Active Tuberculosis. *J Infect Dis* 2020; 222(12): 2093-102.
- 41. Peschke B, Keller CW, Weber P, Quast I, Lunemann JD. Fc-Galactosylation of Human
  Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent
  Cytotoxicity. *Front Immunol* 2017; 8: 646.
- 558 42. Carvelli J, Demaria O, Vely F, et al. Association of COVID-19 inflammation with activation
  559 of the C5a-C5aR1 axis. *Nature* 2020; **588**(7836): 146-50.

- 560 43. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G 561 resulting from Fc sialylation. *Science* 2006; **313**(5787): 670-3.
- 562 44. Washburn N, Schwab I, Ortiz D, et al. Controlled tetra-Fc sialylation of IVIg results in a drug
- candidate with consistent enhanced anti-inflammatory activity. *Proc Natl Acad Sci U S A* 2015;
   **112**(31): E4339.
- 565 45. Quast I, Keller CW, Maurer MA, et al. Sialylation of IgG Fc domain impairs complement-
- 566 dependent cytotoxicity. *J Clin Invest* 2015; **125**(11): 4160-70.

567

# SUPPORTING INFORMATION

#### medRxiv

#### Immunoglobulin G1 Fc glycosylation as an early hallmark of severe COVID-19

Tamas Pongracz<sup>1,\*</sup>, Jan Nouta<sup>1</sup>, Wenjun Wang<sup>1</sup>, Krista. E. van Meijgaarden<sup>4</sup>, Federica Linty<sup>2,3</sup>, Gestur Vidarsson<sup>2,3</sup>, Simone A. Joosten<sup>4</sup>, Tom H. M. Ottenhoff<sup>4</sup>, Cornelis H. Hokke<sup>5</sup>, Jutte J. C. de Vries<sup>6</sup>, Sesmu M. Arbous<sup>7</sup>, Anna H. E. Roukens<sup>7</sup>, Manfred Wuhrer<sup>1</sup> in collaboration with BEAT-COVID<sup>#</sup> and COVID-19<sup>&</sup> groups

<sup>1</sup>Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands

<sup>2</sup>Dept. of Experimental Immunohematology, Sanquin Research, Amsterdam, Netherlands

<sup>3</sup>Landsteiner Laboratory, Amsterdam University Medical Center, Amsterdam, Netherlands

<sup>4</sup>Dept. of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands

<sup>5</sup>Dept. of Parasitology, Leiden University Medical Center, Leiden, Netherlands

<sup>6</sup>Dept. of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands

<sup>7</sup>Dept. of Intensive Care, Leiden University Medical Center, Leiden, Netherlands

\*BEAT-COVID group (in alphabetical order, investigators): B. M. van den Berg<sup>2</sup>, S. Cannegieter<sup>3</sup>, C. M. Cobbaert<sup>4</sup>, A. van der Does<sup>5</sup>, J. J. M. van Dongen<sup>6</sup>, H. C. J. Eikenboom<sup>7</sup>, M. C. M. Feltkamp<sup>8</sup>, A. Geluk<sup>9</sup>, J. J. Goeman<sup>10</sup>, M. Giera<sup>11</sup>, T. Hankemeier<sup>12</sup>, M. H. M. Heemskerk<sup>13</sup>, P. S. Hiemstra<sup>5</sup>, J. J. Janse<sup>14</sup>, S. P. Jochems<sup>14</sup>, M. Kikkert<sup>8</sup>, L. Lamont<sup>12</sup>, J. Manniën<sup>10</sup>, M. R. del Prado<sup>1</sup>, N. Queralt Rosinach<sup>15</sup>, M. Roestenberg<sup>14</sup>, M. Roos<sup>15</sup>, H. H. Smits<sup>14</sup>, E. J. Snijder<sup>8</sup>, F. J. T. Staal<sup>6</sup>, L. A. Trouw<sup>6</sup>, R. Tsonaka<sup>10</sup>, A. Verhoeven<sup>11</sup>, L. G. Visser<sup>9</sup>, J. J. C. de Vries<sup>8</sup>, D. J. van Westerloo<sup>1</sup>, J. Wigbers<sup>1</sup>, H. J. van der Wijk<sup>10</sup>, R. C. van Wissen<sup>4</sup>, M. Yazdanbakhsh<sup>14</sup>, M. Zlei<sup>6</sup>

<sup>1</sup>Dept. of Intensive Care, Leiden University Medical Center, Leiden, Netherlands

<sup>2</sup>Dept. of Internal Medicine, Nephrology, Leiden University Medical Center, Leiden, Netherlands

<sup>2</sup>Dept. of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands

<sup>4</sup>Dept. of Clinical Chemistry, Leiden University Medical Center, Leiden, Netherlands

<sup>5</sup>Dept. of Pulmonary Medicine, Leiden University Medical Center, Leiden, Netherlands

<sup>6</sup>Dept. of Immunology, Leiden University Medical Center, Leiden, Netherlands

<sup>7</sup>Dept. of Internal Medicine, Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, Netherlands

<sup>8</sup>Dept. of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands

<sup>9</sup>Dept. of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands

<sup>10</sup>Dept. of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands

<sup>11</sup>Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands

<sup>12</sup>Dept. of Analytical Biosciences, Leiden Academic Centre for Drug Research, Leiden, Netherlands

<sup>13</sup>Dept. of Hematology, Leiden University Medical Center, Leiden, Netherlands

<sup>14</sup>Dept. of Parasitology, Leiden University Medical Center, Leiden, Netherlands

<sup>15</sup>Dept. of Human Genetics, Leiden University Medical Center, Leiden, Netherlands

**COVID-19 group** (in alphabetical order, investigators):

M. Baysan<sup>2,3</sup>, M. G. J. de Boer<sup>4</sup>, A. G. van der Bom<sup>3</sup>, O. M. Dekkers<sup>3</sup>, A. M. Eikenboom<sup>3</sup>, S. B. ter Haar<sup>3</sup>, L. Heerdink<sup>3</sup>, L. J. van Heurn<sup>3</sup>, I. de Jonge<sup>3</sup>, W. Lijfering<sup>3</sup>, R. Meier<sup>1</sup>, J. A. Oud<sup>1</sup>, F. Rosendaal<sup>3</sup>, A. G. L. Toppenberg<sup>3</sup>, J. Uzorka<sup>4</sup>, A. A. van IJIzinga Veenstra, J. Wigbers<sup>2</sup>, J. M. Wubbolts<sup>4</sup>

<sup>1</sup>Dept. of Hematology, Leiden University Medical Center, Leiden, Netherlands

<sup>2</sup>Dept. of Intensive Care, Leiden University Medical Center, Leiden, Netherlands

<sup>3</sup>Dept. of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands

<sup>4</sup>Dept. of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands

#### \*Correspondence:

Tamas Pongracz

Albinusdreef 2, 2223ZA, Leiden, Netherlands

Tel: +31 71 526 8701 <u>t.pongracz@lumc.nl</u>

![](_page_20_Figure_1.jpeg)

**Supplementary Figure 1. Age and sex distribution in the BEAT-COVID cohort.** Overall 159 patients participated in the study (39 female and 119 male, 1 unknown (not shown)). The color illustrates ICU (red) and non-ICU (blue) treatment groups, whereas the number in the circles indicates the number of patients in the corresponding group.

![](_page_21_Figure_0.jpeg)

medRxiv preprint doi: https://doi.org/10.1101/2021.11.18.21266442; this version posted November 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Supplementary Figure 2. Anti-S (blue) and total (yellow) IgG1 bisection, galactosylation and sialylation are confounded by age in a similar way, which is eliminated by normalizing to total IgG1 levels. IgG1 (A) fucosylation, (C) bisection, (E) galactosylation and (G) sialylation as a proxy of age in female (left) and male (right) patients. Corresponding delta ( $\Delta$ ) IgG1 (B) fucosylation and (D) bisection, (F) galactosylation and (H)

medRxiv preprint doi: https://doi.org/10.1101/2021.11.18.21266442; this version posted November 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. sialylation levels (all in grey), as normalized to total IgG levels by subtracting total from anti-S IgG1 glycosylation levels. Baseline timepoints are shown. Shown in the inset are the Spearmen correlation coefficients (R) and *p*-values, respectively. IgG1 bisection is known to increase, whereas galactosylation and sialylation are known to decrease upon aging.<sup>1</sup> Correction for the age confounding effect was performed by normalizing to total IgG levels, as illustrated by the weak and non-significant Spearman correlations and *p*-values, respectively (**B**, **D**, **F**, **H**).

![](_page_22_Figure_1.jpeg)

Supplementary Figure 3. Comparison of  $\Delta$ glycosylation traits of female and male patients demonstrates the absence of a sex confounding effect. IgG1 (A)  $\Delta$ fucosylation, (B)  $\Delta$ galactosylation, (C)  $\Delta$ bisection and (D)  $\Delta$ sialylation. Correction for the age and sex confounding effect was performed as described above (Figure S2).

![](_page_23_Figure_0.jpeg)

medRxiv preprint doi: https://doi.org/10.1101/2021.11.18.21266442; this version posted November 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Supplementary Figure 4. AIgCI glycosylation dynamics during the entire hospitalization period. The time-

Supplementary Figure 4. AIgG1 glycosylation dynamics during the entire hospitalization period. The timecourse of  $\Delta$ glycosylation derived traits (A) fucosylation, (B) galactosylation, (C) bisection and (D) sialylation, as shown during hospitalization (n=111). Line colours correspond to a single COVID-19 patient, whilst the colour gradient in the circles/squares indicates the corresponding severity score (grey = NA). The shape displays whether a patient passed away (square) or was discharged alive (circle). The black dashed line with a grey 95% confidence interval band is a cubic polynomial fit over the shown datapoints to illustrate overall dynamics.

![](_page_25_Figure_0.jpeg)

medRxiv preprint doi: https://doi.org/10.1101/2021.11.18.21266442; this version posted November 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Supplementary Figure 5. ΔIgGI glycosylation dynamics of the subset of patients with a follow-up sample.

Supplementary Figure 5. AIgG1 glycosylation dynamics of the subset of patients with a follow-up sample. The time-course of  $\Delta$ glycosylation derived traits (A) fucosylation, (B) galactosylation, (C) bisection and (D) sialylation, as shown during the hospitalization period and follow-up (n=19). Line colours correspond to a single COVID-19 patient, whilst the colour gradient in the circles/squares indicates the corresponding severity score (grey = NA). The circle and shape display whether the timepoint corresponds to a follow-up sample (square) or to a sample taken during hospitalization (circle). The black dashed line with a grey 95% confidence interval band is a cubic polynomial fit over the shown datapoints to illustrate overall dynamics.

![](_page_27_Figure_0.jpeg)

![](_page_28_Figure_0.jpeg)

![](_page_28_Figure_1.jpeg)

medRxiv preprint doi: https://doi.org/10.1101/2021.11.18.21266442; this version posted November 20, 2021. The copyright holder for this

period. The time-course of glycosylation derived traits (A) fucosylation, (B) bisection, (C) galactosylation and (D) sialylation as shown during the hospitalization period (n=111). Anti-S IgG1 dynamics are shown in the left facets, whereas total IgG1 dynamics in the right facets in each panel. Line colors correspond to a single COVID-19 patient, whilst the colour gradient in the circles/squares indicates the corresponding severity score (grey = NA). The circle and shape display whether the patient passed away (square) or was discharged alive (circle) from the hospital. The black dashed line with a grey 95% confidence interval band is a cubic polynomial fit over the shown datapoints to illustrate overall dynamics. Note that the confounding effect of age largely influences the observed bisection (Figure S2C), galactosylation (Figure S2E) and (Figure S2G) sialylation pattern, thereby has been corrected for age effects (Figure S2).

![](_page_30_Figure_0.jpeg)

Supplementary Figure 7. ICU (red) and non-ICU (blue) patients and corresponding  $\Delta$ IgG1 glycosylation derived traits in a "days since onset of symptoms" subset of patients (n=129) to confirm that the observed differences (Figure 3) are not confounded by vast glycosylation dynamics.  $\Delta$ IgG1 (A) fucosylation, (C) bisection, (E) galactosylation and (G) sialylation as a proxy of days since symptom onset. Shown in the inset are

medRxiv preprint doi: https://doi.org/10.1101/2021.11.18.21266442; this version posted November 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. the Spearmen correlation coefficients (R) and *p*-values, respectively. The red (ICU) and blue (non-ICU) lines are

All rights reserved. No reuse allowed without permission. the Spearmen correlation coefficients (R) and *p*-values, respectively. The red (ICU) and blue (non-ICU) lines are linear regression lines and the corresponding band indicates the 95% confidence interval. The dashed vertical lines indicate group means. Comparison of corresponding  $\Delta$ IgG1 (**B**) fucosylation, (**D**) bisection, (**F**) galactosylation and (**H**) sialylation levels between ICU and non-ICU patients. All datapoints correspond to baseline samples (time of hospitalization).

![](_page_31_Figure_2.jpeg)

Supplementary Figure 8. AIgG1 Aglycosylation dynamics of patients admitted to the ICU (n=48; red) and non-ICU (n=34; blue) treatments as shown between days 10 and 25. The time course of  $\Delta$ IgG1 glycosylation traits (A) fucosylation, (B) galactosylation, (C) bisection and (D) sialylation. The dashed lines with 95% confidence interval bands are cubic polynomials fit over the shown datapoints to illustrate overall dynamics.

![](_page_32_Figure_0.jpeg)

medRxiv preprint doi: https://doi.org/10.1101/2021.11.18.21266442; this version posted November 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Supplementary Figure 9. Patients in varying severity score groups 0-5 (red), 6-11 (green) and 12-17 (dark

Supplementary Figure 9. Patients in varying severity score groups 0-5 (red), 6-11 (green) and 12-17 (dark blue) and corresponding  $\Delta$ IgG glycosylation derived traits in a "days since onset of symptoms" subset of patients to confirm that the observed differences (Figure 4) are not confounded by vast glycosylation dynamics.  $\Delta$ IgG1 (A) fucosylation and (C) bisection, (E) galactosylation and (G) sialylation as a proxy of days since onset of subset of patients. Shown in the inset are the Spearmen correlation coefficients (R) and *p*-values, respectively. The red (0-5), green (6-11) and blue (12-17) lines are linear regression lines and the corresponding band indicates the 95% confidence interval. Dashed vertical lines indicate group mean. Comparison of corresponding  $\Delta$ IgG1 (B) fucosylation and (D) bisection, (F) galactosylation and (H) sialylation levels between the three severity score groups. Circle indicates ICU patients, whereas squares indicate non-ICU patients. All datapoints correspond to baseline samples (time of hospitalization).

![](_page_34_Figure_0.jpeg)

Supplementary Figure 10. Comparison of acute respiratory distress syndrome (A-D), survival (E-H) and ventilation (I-L) subgroups of patients for glycosylation traits fucosylation (A, E, I), bisection (B, F, J), galactosylation (C, G, K) and sialylation (D, H, L). Bisection negatively associated with, survival, and sialylation negatively associated with ventilation. No other associations were found.

#### References

1. Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. *Cell Immunol* 2018; **333**: 65-79.